Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716794 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of HE3235 in Patients With Prostate Cancer
A Phase 1 study, sponsored by Harbor Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00716794 is a Phase 1 study that has completed, run by Harbor Therapeutics. The registered enrollment target is 64 participants.
The verdict
NCT00716794, a Phase 1 study, has completed, sponsored by Harbor Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to patients with advanced prostate cancer who have failed hormone therapy and at least one taxane based chemotherapy regimen.
Interventions
- DRUG HE3235
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716794
The ClinicalTrials.gov registry entry for NCT00716794 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harbor Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HE3235 is the first listed.
NCT00716794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00716794 about?
NCT00716794 is a clinical study titled "A Phase I/II Study of HE3235 in Patients With Prostate Cancer". This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to patients with advanced prostate cancer who have failed hormone therapy and at least one taxane based chemotherapy regimen.
What is the current status of trial NCT00716794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2008-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00716794?
The interventions under investigation include: HE3235 (DRUG).
Who is sponsoring clinical trial NCT00716794?
This trial is sponsored by Harbor Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.